Navigation Links
Medical Marijuana Inc. Portfolio Company CanChew BioTechnologies Inc. Announces Final Three Days for Market Survey and Free Product Trial Registration
Date:11/13/2012

SAN DIEGO, Nov. 13, 2012 /PRNewswire/ -- CanChew BioTechnologies Inc, a portfolio company of Medical Marijuana Inc. (OTC: MJNA), announces that this week marks the final three days to register for the market trial of CanChew gum.  Qualifying participants will receive a minimum of a 30-day free trial sample of the CBD-based CanChew gum in exchange for their product feedback.  The only cost involved will be a nominal shipping charge of $4.95 for delivery of the product. 

While the company has been researching distribution partnerships for over-the-counter sales of the CanChew gum product, preparations for clinical trials have been underway in Europe and are slated to begin during 2013.  U.S. clinical trials should begin shortly thereafter.  Successful trials and new drug application may eventually lead to a European and/or U.S. pharmaceutical product with substantiated medical claims. Over the counter sales of CanChew gum are expected to begin in the first quarter of 2013. 

Ted Caligiuri, President and CEO of Medical Marijuana Inc. comments: "We are pleased with the interest in our CanChew market survey and free product trial and eagerly anticipate positive feedback from clients."

The gum contains high concentrations of CBD hemp oil and its raw ingredients are derived from the operations of PhytoSphere systems, an MJNA portfolio company.  MJNA anticipates selling these products through the Internet, as well portfolio company Red Dice Holdings national distribution platform. Currently, Red Dice Holdings distributes a variety of CBD Hemp oil products in over 500 retail locations throughout Colorado, Arizona, California and New Mexico.

Please visit this link to sign up for the market trial: http://www.canchewbiotech.com/component/users/?view=registration

About CanChew
CanChew® is a unique, socially acceptable, patient friendly, taste masked and convenient delivery format for delivery of cannabis/cannabinoid(s) based pharmaceuticals. The delivery of these medications via the oral mucosa provides for rapid and near complete absorption directly into the systemic circulation. This leads to rapid onset of effects and increased bioavailability. Pre-systemic metabolism is thus avoided. This system of delivery offers clearly improved economic opportunities compared to alternative drug delivery routes. 

About Medical Marijuana, Inc.                                                                                               Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value.

Medical Marijuana Inc. does not grow, sell or distribute any substances that violate United States Law or the controlled substance act.

For more information, please visit the company's website at: www.MedicalMarijuanaInc.com

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration (FDA). These products and statements are not intended to diagnose, treat, cure, or prevent any disease.

Corporate Contact:

Medical Marijuana, Inc.
Toll Free: 888-OTC-MJNA (888-682-6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc 
Investor Relations Contact:
Stuart T. Smith
SmallCapVoice.Com, Inc.
P. 512-267-2430
F. 512-267-2530
Email: ssmith@smallcapvoice.com
Skype: SmallCapVoice.com
AIM: SmallCapVoice7


'/>"/>
SOURCE Medical Marijuana Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Varian Medical Systems to Exhibit Flat Panel Detectors, X-Ray Tubes and Imaging Software Optimized for Digital Radiography at MEDICA
2. RPS Announces Jonathan M. Fishbein, MD as Executive Vice President and Chief Medical Officer
3. Dukes Ralph Snyderman, M.D. Joins SenGenix as Senior Medical Advisor and Board Member
4. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
5. Medical Device Study Presents Detailed View of Key Budget and Staffing Metrics for Marketing Groups
6. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
7. Sony Medical Division Teams with Wills Eye Institute to Bring "Expert" Panel of Ophthalmologists to AAO 2012 Convention
8. STD Med Inc. Receives ANVISA Registration for Class III Medical Devices in Brazil
9. Mount Sinai Medical Center 1st in Tri-State Area to Discharge Patient without Human Heart
10. Concord Medical Announces Change to Third Quarter Financial Results Date to November 20, 2012
11. Winner Medical Announces Mailing of Definitive Proxy Materials for Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology:
(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... application containerization, today announced it will co-exhibit with technology partners LG Business Solutions ... at the Marriott Metro Center in Washington D.C., will provide education and examination ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds ... highest industry standards and specifications such as ANSI, ISO and proven test methods ...
(Date:3/27/2017)... ... 2017 , ... Osteitis pubis may be commonplace and seemingly ... occurs when the muscles around the pelvis become inflamed. Over time, untreated osteitis ... as well as accompanying tenderness and weakness. Without proper intervention, it can hinder ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a Farmingdale, ... recent RNA methylation “gold rush” with their established portfolio of optimized assay kits ... N6-methyladenosine, or m6A , RNA methylation has received a new burst in ...
(Date:3/27/2017)... San Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still ... one of the best days I’ve had in a long time,” she said. , She ... a lot of money that I never thought I would have to help my students.” ...
Breaking Medicine News(10 mins):